CoChat

Fecal neutrophil gelatinase‐associated lipocalin as a biomarker for inflammatory bowel disease

Open access
Thorsvik, Silje, Damås, Jan Kristian, Granlund, Atle vB, Flo, Trude Helen, Bergh, Kåre, Østvik, Ann Elisabet, Sandvik, Arne Kristian · 2017 · Journal of Gastroenterology and Hepatology
Cited by 100

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Background and Aim: Accurate, noninvasive biomarkers are needed to diagnose and monitor inflammatory bowel disease (IBD). Neutrophil gelatinase‐associated lipocalin (NGAL), also known as lipocalin 2, is expressed in inflamed colonic epithelium and neutrophilic granulocytes. This study explores its properties as a biomarker in feces and plasma and, for the first time, compares fecal NGAL systematically with the existing fecal biomarker calprotectin. Methods: Neutrophil gelatinase‐associated lipocalin was measured in feces from 73 patients with IBD, 21 patients with infectious enterocolitis, 21 patients with irritable bowel syndrome, and 23 healthy subjects using ELISA. The results were correlated to calprotectin, clinical score, endoscopic score, and high‐sensitive C‐reactive protein. Plasma from 119 patients with IBD and 28 healthy controls was analyzed for NGAL. Results: Fecal NGAL levels (median and interquartile range) were significantly elevated in active ulcerative colitis (UC) 6.05 (3.6–15.1) mg/kg and Crohn's disease (CD) 4.9 (1.5–7.7) mg/kg, compared with patients with inactive UC 1.3 (0.4–2.6) mg/kg, inactive CD 1.5 (0.5–1.7) mg/kg, irritable bowel syndrome 0.4 (0.2–0.6) mg/kg, and healthy controls (HC) 0.3 (0.1–0.4) mg/kg. Patients with infectious enterocolitis had significantly higher fecal‐NGAL levels, 2.7 (1.4–5.6) mg/kg than HC. Sensitivity and specificity was 94.7% and 95.7%, respectively, for distinguishing between active IBD and HC. Stability of NGAL in stool was excellent for 7 days in room temperature. Plasma NGAL was significantly elevated in UC and CD compared with HC. Conclusions: Fecal NGAL is a promising biomarker for IBD. As existing biomarkers are expressed mainly in granulocytes, NGAL's epithelial localization may give supplementary diagnostic information.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jgh.13598

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 100

Metadata

Authors
Thorsvik, S., Damås, J. K., Granlund, A. V., Flo, T. H., Bergh, K., Østvik, A. E., & Sandvik, A. K.
Venue
Journal of Gastroenterology and Hepatology
Publisher
Wiley
Published
2017-01
Volume
32
Issue
1
Pages
128-135
ISSN
  • 0815-9319 (ISSN-L)
  • 1440-1746
OpenAlex
W2519777062
Cited by
100
References
4
FWCI
5.63
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fecal neutrophil gelatinase‐associated lipocalin as a biomarker for inflammatory bowel disease. https://app.cochat.ai/papers/10.1111/jgh.13598
The paper
Thorsvik, S., Damås, J. K., Granlund, A. V., Flo, T. H., Bergh, K., Østvik, A. E., & Sandvik, A. K. (2017). Fecal neutrophil gelatinase‐associated lipocalin as a biomarker for inflammatory bowel disease. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.13598

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.